Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.8.0.1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
 6 Months Ended 12 Months Ended
Oct. 16, 2012
Nov. 30, 2017
May 31, 2016
May 31, 2017
May 31, 2015
Commitments and Contingencies [Line Items]          
Asset purchase, cash paid $ 3,500,000        
Asset Purchase Agreement Aggregate Consideration Paying Period     10 years    
Payment to acquire other assets     $ 1,500,000    
Accrued milestone payments         $ 2,500,000
Prepaid execution fees for process validation and manufacturing activities   $ 3,143,385   $ 4,138,041  
Milestone Payments          
Commitments and Contingencies [Line Items]          
Royalty on every net sales     5.00%    
Development Milestone Payments          
Commitments and Contingencies [Line Items]          
Asset Purchase Agreement Aggregate Consideration Paying Period     10 years    
Payment to acquire other assets     $ 1,000,000    
Minimum annual license maintenance fees     150,000    
Project Work Order | Termination of Any One Clinical Trial | Minimum          
Commitments and Contingencies [Line Items]          
Financial penalties   100,000      
Project Work Order | Termination of Any One Clinical Trial | Maximum          
Commitments and Contingencies [Line Items]          
Financial penalties   300,000      
Project Work Order | Termination of All Clinical Trials | Minimum          
Commitments and Contingencies [Line Items]          
Financial penalties   500,000      
Project Work Order | Termination of All Clinical Trials | Maximum          
Commitments and Contingencies [Line Items]          
Financial penalties   1,600,000      
Contract Manufacturing Companies          
Commitments and Contingencies [Line Items]          
Execution fees incurred for process validation and manufacturing activities   3,200,000      
Prepaid execution fees for process validation and manufacturing activities   2,100,000      
Contract Manufacturing Companies | Termination of Any One Clinical Trial | Maximum          
Commitments and Contingencies [Line Items]          
Financial penalties   $ 4,000,000      
First dosing in a U.S. Phase 3 trial or non-US equivalent | Milestone Payments          
Commitments and Contingencies [Line Items]          
Potential future milestone and royalties payments     1,500,000    
First dosing in a U.S. Phase 3 trial or non-US equivalent | Development Milestone Payments          
Commitments and Contingencies [Line Items]          
Potential future milestone and royalties payments     1,000,000    
First US new drug application approval by the FDA or other non-U.S. approval | Milestone Payments          
Commitments and Contingencies [Line Items]          
Potential future milestone and royalties payments     5,000,000    
Biologic License Application with the FDA or non-U.S. equivalent regulatory body | Development Milestone Payments          
Commitments and Contingencies [Line Items]          
Potential future milestone and royalties payments     500,000    
FDA approval or approval by another non-U.S. equivalent regulatory body | Development Milestone Payments          
Commitments and Contingencies [Line Items]          
Potential future milestone and royalties payments     $ 500,000    
Royalty on every net sales     7.50%